Compare ATMU & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | ADMA |
|---|---|---|
| Founded | 1958 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.6B |
| IPO Year | 2023 | 2012 |
| Metric | ATMU | ADMA |
|---|---|---|
| Price | $55.69 | $14.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $59.75 | $32.00 |
| AVG Volume (30 Days) | 675.9K | ★ 3.4M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | ★ 2.50 | 0.60 |
| Revenue | ★ $1,764,300,000.00 | $42,219,783.00 |
| Revenue This Year | $15.23 | $27.46 |
| Revenue Next Year | $4.28 | $21.11 |
| P/E Ratio | ★ $22.64 | $24.71 |
| Revenue Growth | 5.67 | ★ 43.85 |
| 52 Week Low | $30.94 | $13.76 |
| 52 Week High | $66.50 | $25.67 |
| Indicator | ATMU | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 39.18 |
| Support Level | $51.05 | $13.79 |
| Resistance Level | $58.18 | $15.84 |
| Average True Range (ATR) | 1.89 | 0.72 |
| MACD | -0.74 | -0.03 |
| Stochastic Oscillator | 6.14 | 4.65 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.